MCRB - Seres Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617-945-9626
http://www.serestherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees145

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric D. ShaffPres, CEO, Interim Principal Financial Officer & Director561.92kN/A1976
Dr. John G. AuninsCTO and Exec. VP of Bioprocess & ManufacturingN/AN/A1961
Dr. Matthew R. HennExec. VP & Chief Scientific OfficerN/AN/A1975
Mr. Carlo TanziVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Thomas J. DesRosierChief Legal Officer, Exec. VP & Sec.N/AN/A1955
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Seres Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.